SAM
FTH

Serengeti Asset Management’s Faeth Therapeutics FTH Stock Holding History

Serengeti Asset Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$291K – 62
2021
Q1 		$291K Buy
+1,000
New +$335K 0.13% 26

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
FG
Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Serengeti Asset Management's FTH Position: Q2 2021 in Review

Serengeti Asset Management sold out of Faeth Therapeutics (FTH) in Q2 2021, closing a stake of 1,000 shares — an estimated $291K sold.

Serengeti Asset Management first reported a position in FTH in Q1 2021 and held it in 1 quarter. The position peaked at $291K in Q1 2021. 34 funds tracked by Wall St. Rank hold FTH as of Q2 2021.

  • Serengeti Asset Management reported no remaining Faeth Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Serengeti Asset Management sold 1,000 Faeth Therapeutics shares in Q2 2021, an estimated $291K.
  • Serengeti Asset Management first reported a position in Faeth Therapeutics in Q1 2021 and held it in 1 quarter.
  • Serengeti Asset Management's Faeth Therapeutics position peaked at $291K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2021.

Based on Serengeti Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.